Clinical Chemistry Analyzer Processes 300 Tests per Hour

A clinical chemistry analyzer has been launched for low- to medium-volume laboratories with throughput needs of up to 300 tests per hour.

Compact and reliable, the cobas c 311 analyzer is suitable for satellite, STAT, and smaller hospital laboratories. It offers a comprehensive clinical chemistry menu of more than 100 assays. Up to 45 assays can be performed simultaneously. High onboard reagent stabilities and lot-to-lot calibration optimize reagent usage makes the analyzer cost-effective and convenient to use.

All reagents in the ergonomic cobas c packs are liquid and ready-to-use, and all components of a parameter are integrated into a single cassette. The integration of cobas e-services for electronic updates and downloads makes handling of application, calibrator, and control information seamless and precise. Special features of the 311 analyzer include intelligent clot detection, carryover-free ultrasonic mixing, and test-specific serum indices.

Introduced by Roche (Basel, Switzerland), the cobas c 311 analyzer represents the latest collaboration between the company and its strategic partner, Hitachi High Technologies (Tokyo, Japan). The analyzer was launched prior to the American Association of Clinical Chemistry (AACC) Congress, which was held on July 29-31, 3008, in Washington DC (USA). Dirk Ehlers, head of Roche professional diagnostics said, "The system will enable us to offer smaller laboratories many of the efficiencies and conveniences currently provided by the cobas 6000 analyzer series.”

The cobas c 311 analyzer complements the cobas 411 immunoanalyzer, which was released in December 2006. The two systems compose the cobas 4000 analyzer series, an efficient serum work-area solution designed to process more than 95% of the combined testing needs of low- to mid-volume laboratories.

Roche, a biotech company, is an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.


Related Links:
Roche
Hitachi High Technologies